Zobrazeno 1 - 10
of 389
pro vyhledávání: '"Victor L. Serebruany"'
Publikováno v:
TH Open, Vol 05, Iss 04, Pp e503-e506 (2021)
TH Open: Companion Journal to Thrombosis and Haemostasis
TH Open: Companion Journal to Thrombosis and Haemostasis
Background Cardiovascular benefits of aggressive dual antiplatelet therapy may be associated with extra risks including bleeding, cancer, and infections discovered first for prasugrel in the TRial to assess Improvement in Therapeutic Outcomes by opti
Publikováno v:
Reviews in Cardiovascular Medicine, Vol 22, Iss 3, Pp 553-555 (2021)
No abstract present.
Autor:
Julia Docenko, Nikita Lomakin, Victor L. Serebruany, Arthur Melkumyants, Liudmila Buryachkovskaya
Publikováno v:
Reviews in Cardiovascular Medicine, Vol 22, Iss 3, Pp 549-551 (2021)
No abstract present.
Autor:
Enze Jin, Victor L. Serebruany, Jia-Xin Li, Moo Hyun Kim, Jin-Yeong Han, Soo Jin Kim, Kwang Min Lee, Kai Song, LongZhe Guo
Publikováno v:
Clinical & Experimental Thrombosis and Hemostasis. 6:6-11
Autor:
James Swan, Cheol-Whan Lee, Kiyuk Jang, Wolfgang Eisert, Mario Alberto Benavides, Victor L. Serebruany, Junghan Yoon, Jean-François Tanguay, Moo Hyun Kim, Thomas A. Marciniak, Hector A. Cabrera-Fuentes
Publikováno v:
American Journal of Therapeutics
Background Excess vascular deaths in the PLATO trial comparing ticagrelor to clopidogrel have been repeatedly challenged by the Food and Drug Administration (FDA) reviewers and academia. Based on the Freedom of Information Act, BuzzFeed won a court o
Publikováno v:
The American Journal of Medicine. 133:347-351
Background Ivabradine, a heart rate-slowing drug used to treat heart failure and (in Europe) angina, had varying impacts upon cardiovascular events in its 3 large outcome trials. Food and Drug Administration (FDA) analyses may explain the reasons for
Publikováno v:
European Cardiology Review, Vol 14, Iss 3, Pp 175-178 (2019)
European Cardiology Review
European Cardiology Review
Some patients treated with dual antiplatelet therapy (DAPT) following acute coronary syndrome (ACS) can still exhibit heightened residual platelet reactivity (HRPR), which is potentially linked to adverse vascular outcomes. Better tailored DAPT strat
Autor:
Stefan Agewall, Jesper K. Jensen, Thomas G. von Lueder, Ingrid Hopper, Dipak Kotecha, Dan Atar, Moo Hyun Kim, Victor L. Serebruany, Robert J. Mentz
Publikováno v:
von Lueder, T G, Atar, D, Agewall, S, Jensen, J K, Hopper, I, Kotecha, D, Mentz, R J, Kim, M H & Serebruany, V L 2019, ' All-Cause Mortality and Cardiovascular Outcomes With Non-Vitamin K Oral Anticoagulants Versus Warfarin in Patients With Heart Failure in the Food and Drug Administration Adverse Event Reporting System ', American Journal of Therapeutics, vol. 26, no. 6, pp. e671-e678 . https://doi.org/10.1097/MJT.0000000000000883
BACKGROUND: Many patients with heart failure (HF) are treated with warfarin or non-vitamin K oral anticoagulants (NOACs). Randomized outcome-driven comparisons of different anticoagulant strategies in HF are lacking. Data from international, governme
Impact of VKORC1, CYP2C9, and CYP4F2 Polymorphisms on Optimal Warfarin Dose: Does Ethnicity Matters?
Autor:
Soo J Kim, Long Z Guo, Kai Song, Moo H Kim, Kwang M Lee, Jia X Li, En Z Jin, Victor L. Serebruany
Publikováno v:
American journal of therapeutics. 28(4)
BACKGROUND Conventional anticoagulation with warfarin remains the cornerstone strategy for numerous preventive strategies. It is established that Asian patients require lower warfarin doses than Caucasians potentially attributing to the genetic polym
Publikováno v:
Journal of Clinical Medicine, Vol 10, Iss 3140, p 3140 (2021)
Journal of Clinical Medicine
Volume 10
Issue 14
Journal of Clinical Medicine
Volume 10
Issue 14
The potential link between antiplatelet agents and anticoagulants with excess cancer deaths (CD) was reported first for prasugrel (TRITON, DAPT), clopidogrel (DAPT), vorapaxar (TRACER), apixaban (APPRAISE-2), and later ticagrelor (PEGASUS). However,